Slowing of Peripheral Artery Disease: Another Liraglutide Benefit?
(MedPage Today) -- Liraglutide (Victoza), a type 2 diabetes drug, may help prevent peripheral artery disease (PAD) progression, the small, open-label STARDUST trial suggested.
Over 6 months, adults with type 2 diabetes on subcutaneous liraglutide...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Peripheral Vascular Disease (PVD) | Victoza